The company priced 16M shares at $18 each.
That's the top of a marketed range of $16-$18 each, making for a raise of $288M.
The company is run by biotech veterans Arie Belldegrun and David C. Chang.
It's set to debut tomorrow on Nasdaq Global Select Market.
Previously: Allogene sets terms of IPO (Oct. 02 2018)
Previously: Allogene Therapeutics readies IPO (Sep. 14 2018)
Subscribe for full text news in your inbox